Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in clinical trials: a Pharma Matters report.

A Arjona1, B Nuskey2, X Rabasseda3

  • 1Thomson Reuters, Barcelona, Spain. scientificprousjournals@thomsonreuters.com.

Drugs of Today (Barcelona, Spain : 1998)
|September 5, 2014
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative identification of Contracaecum sp. (Nematoda: Anisakidae) from grey mullet Mugil cephalus and cormorant Phalacrocorax gaimardi in the Southeastern Pacific Ocean off Peru.

Veterinary parasitology, regional studies and reports·2025
Same author

Ultra-processed vegan foods: Healthy alternatives to animal-source foods or avoidable junk?

Journal of food science·2024
Same author

Management of cerebral venous thrombosis in Spain: MOTIVATE descriptive study.

Neurologia·2023
Same author

Management of cerebral venous thrombosis in Spain: MOTIVATE descriptive study.

Neurologia·2021
Same author

Monitoring spatiotemporal changes in chaperone-mediated autophagy in vivo.

Nature communications·2020
Same author

Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Big data and advanced technologies are revolutionizing clinical trials, enhancing patient recruitment and enabling risk-based monitoring. Challenges like data privacy and variability require careful consideration for future advancements.

Area of Science:

  • Pharmaceutical industry
  • Clinical trials
  • Dermatology

Background:

  • The pharmaceutical industry faces increasing complexity in drug development.
  • Big data and new technologies offer potential solutions for clinical trials.
  • Focus on centralized data and risk-based monitoring is transforming trial management.

Purpose of the Study:

  • To review novel therapies for psoriasis and atopic dermatitis.
  • To highlight the impact of big data in clinical research.
  • To discuss the methodology of risk-based monitoring in clinical trials.

Main Methods:

  • Review of clinical research reports on novel therapies.
  • Analysis of big data approaches in real-life scenarios.
  • Discussion of risk-based monitoring methodologies.
Keywords:
Big dataClinical trialsDermatologyRisk-based monitoring

Related Experiment Videos

Main Results:

  • Novel therapies for psoriasis and atopic dermatitis show success in Phase II and III studies.
  • Big data enables accelerated patient recruitment and real-time trial monitoring.
  • Risk-based monitoring offers greater efficiency and effectiveness compared to traditional methods.

Conclusions:

  • Big data and technology are pivotal for the future of clinical trials.
  • Addressing challenges such as patient privacy and data variability is crucial.
  • Advancements in clinical trials are improving the management of dermatological diseases.